← Vertex Pharmaceuticals overview

Vertex Pharmaceuticals vs Amgen: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Vertex Pharmaceuticals Inc (VRTX)

Q3 2026
▲3▼1

Vertex beats Q2, buys Crinetics, but faces competition and premium valuation

  • Strong Q2 results and buyback Vertex reported Q2 revenue up 12% to $3.3 billion, raised full-year guidance, and announced a $1.42 billion share buyback. This shows the core business is performing well and returning cash to shareholders.

    This is new financial information that directly reflects the company's current performance and capital return.

  • Crinetics acquisition adds diversification Vertex completed the $10 billion acquisition of Crinetics Pharmaceuticals, adding up to $5 billion in peak annual sales and diversifying beyond cystic fibrosis. The deal is expected to boost revenue immediately and contribute to operating profit by 2029.

    This is a major strategic move that expands Vertex's product portfolio and long-term growth prospects.

  • Pipeline and regulatory wins Casgevy's pediatric expansion, positive inaxaplin kidney data, and a rival CF drug failure strengthen Vertex's outlook. Morgan Stanley initiated coverage with an Overweight rating and a $665 price target.

    These events improve the company's competitive position and future revenue potential.

  • Competition and valuation risks Novartis' Fabhalta is already approved in IgA nephropathy, threatening Vertex's povetacicept (FDA decision due Nov 30, 2026). The Crinetics deal carried a roughly 100% premium, and Vertex trades at a premium valuation with slipping 2026 earnings estimates.

    These are real counterweights that could pressure the stock if execution falters.

August 2026
▲3▼1

Vertex gains on rival CF failure, buyback, and pipeline wins

  • Rival CF drug failure removes competitive threat Sionna's CF drug failure eliminated a potential competitor, strengthening Vertex's dominant position in cystic fibrosis and boosting investor confidence.

    This is a new competitive development that directly benefits Vertex's core franchise.

  • Q2 beat, raised guidance, and $1.42B buyback Vertex reported Q2 revenue of $3.33B (up 12.5%), raised 2026 guidance to $13.1–13.2B, and announced a $1.42B buyback, signaling strong financial health.

    These are new financial updates that directly support the stock price.

  • Non-CF drugs gain traction; pipeline advances Journavx and Casgevy are gaining traction, with non-CF revenue expected to exceed $500M in 2026. Inaxaplin's positive Phase 2 kidney data validated its mechanism, and ALYFTREK advanced in Canada.

    These new pipeline and commercial updates show diversification and future growth potential.

  • Competition and valuation risks persist Novartis' Fabhalta is already approved in IgA nephropathy, posing a threat to Vertex's povetacicept. Vertex trades at a premium valuation, and 2026 earnings estimates have slipped.

    This counterweight highlights ongoing risks that could pressure the stock.

Latest
▲4

Vertex's $10B Crinetics Deal, Kidney Data and ALYFTREK Win Drive Upside

  • Crinetics acquisition adds new endocrine franchise Vertex agreed to buy Crinetics for about $10 billion, adding an approved acromegaly drug and a late-stage hormone disorder treatment. The deal opens a new treatment area beyond cystic fibrosis and is expected to add to operating income by 2029, supporting a higher stock price.

    This is the period's biggest strategic move, diversifying Vertex beyond CF and adding a new growth engine.

  • CASGEVY expanded to young children; ALYFTREK advances in Canada The FDA widened CASGEVY's approval to children as young as 2, growing the number of patients who can get the one-time gene therapy. Vertex also signed a Canadian access deal for ALYFTREK, its next-generation CF drug, moving it toward public reimbursement for about 3,800 patients.

    These regulatory and access wins broaden the patient base for two key products, lifting future sales potential.

  • ALYFTREK restores pancreatic function in young CF children New interim data showed ALYFTREK restored pancreatic function in some children ages 2 to 5 with cystic fibrosis, letting many stop enzyme replacement therapy. This suggests treating CF earlier can reverse damage once thought permanent, strengthening ALYFTREK's long-term role and pricing power.

    This clinical win reinforces Vertex's core CF franchise and could expand ALYFTREK's use and pricing.

  • Kidney drug data validates APOL1 mechanism, but competition looms Positive Phase 2 data for inaxaplin in a kidney disease validated the approach and pointed to a market of over 100,000 patients. However, rivals like Novartis' Fabhalta are already approved, so Vertex must execute well to capture share and justify its pipeline value.

    This confirms a new kidney franchise but also flags real competition that could cap upside.

September 2026
▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex's $10B Crinetics Buy and Kidney Pipeline Progress Drive Upside

  • Crinetics acquisition diversifies beyond CF Vertex completed its $10 billion purchase of Crinetics, adding Palsonify (approved for acromegaly) and atumelnant (late-stage for a hormone disorder). This opens a new treatment area beyond cystic fibrosis, supporting long-term growth and a higher stock price.

    This is the period's biggest new event, directly expanding Vertex's business and analyst price targets.

  • Morgan Stanley starts with Overweight and $665 target Morgan Stanley resumed coverage with an Overweight rating and a $665 price target, citing the Crinetics deal's diversification. The analyst raised Vertex's long-term revenue growth estimate to 13.8% from 12.1%, which helps justify a higher valuation.

    A major analyst upgrade directly influences investor sentiment and price targets.

  • Positive kidney drug data and FDA filing progress Vertex reported positive Phase IIb data for inaxaplin in a kidney disease, showing large reductions in protein in urine, and completed enrollment in a pivotal study. The FDA also accepted its filing for povetacicept, with a decision due Nov. 30, 2026. These advance a new kidney franchise.

    New clinical and regulatory progress adds a potential multi-billion-dollar revenue stream beyond CF.

  • Competition in kidney disease and high deal premium Vertex's kidney pipeline faces competition: Novartis' Fabhalta and other drugs are already approved for IgA nephropathy. Also, Vertex paid a roughly 100% premium for Crinetics, raising the bar for success. These factors could limit upside if execution disappoints.

    Provides a fair counterweight to the positive news, highlighting real risks.

▲3

Vertex Rises as Rival CF Drug Fails and Guidance Climbs

  • Rival CF drug failure clears competitive threat Sionna's SION-719 failed its Phase 2a trial, and the company dropped the program. That removes a would-be competitor to Vertex's cystic fibrosis franchise, which brings in most of its revenue. Less competition means Vertex can keep its dominant share and pricing power, pushing the stock up.

    This is the biggest new event of the period and directly lifts Vertex's core CF business.

  • Q2 revenue beat and raised 2026 guidance Vertex reported Q2 revenue of $3.33 billion, up 12.5% and above estimates, and raised full-year revenue guidance to $13.1–$13.2 billion. It also completed a $1.42 billion share buyback. Strong sales and a brighter outlook support a higher stock price.

    The quarter's results and guidance are the core financial driver behind the stock's move.

  • Non-CF products gaining traction Newer non-CF drugs Journavx and Casgevy posted combined Q2 sales of $126 million, and Vertex expects non-CF revenue to top $500 million in 2026, up about 185%. This shows the company is building growth beyond cystic fibrosis, which supports a higher valuation.

    It shows the post-CF growth story is real, a key reason investors are paying up for the stock.

  • Kidney competition and valuation keep a lid on gains Novartis' Fabhalta is already fully approved for IgA nephropathy, while Vertex's povetacicept faces an FDA decision by Nov. 30, 2026. Vertex also trades at a premium to peers, and 2026 earnings estimates have slipped. These are real counterweights that could limit upside.

    It gives the fair counterweight: competition and a rich valuation could cap further gains.

July 2026
▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

▲3▼1

Vertex's Q2 beat and Crinetics deal drive growth, but kidney competition looms

  • Q2 revenue surges 12% to $3.3B, guidance raised Vertex reported Q2 revenue of $3.3 billion, up 12% year-over-year, driven by CF and newer products. Full-year guidance was raised to $13.1–13.2 billion, and EPS beat expectations. This strong financial performance supports a higher stock price by showing robust demand and execution.

    This is the most recent and direct positive financial update, showing accelerating growth and raised outlook.

  • Crinetics acquisition adds $5B peak sales potential Vertex agreed to acquire Crinetics for $10 billion, gaining paltusotine (PALSONIFY) and atumelnant. The deal is expected to add up to $5 billion in peak revenue and diversify beyond CF. While it uses cash, the strategic fit and growth potential outweigh the cost.

    This is a major strategic move that expands Vertex's rare disease portfolio and long-term growth prospects.

  • Novartis' Fabhalta full approval intensifies kidney competition The FDA granted full approval to Novartis' Fabhalta for IgA nephropathy, a direct competitor to Vertex's povetacicept (target action date Nov 30, 2026). This could limit povetacicept's market share and pricing power, posing a risk to Vertex's kidney pipeline.

    This is a new competitive threat that could impact a key growth driver for Vertex.

  • Casgevy approval expanded to children as young as 2 The FDA expanded Casgevy's approval to treat children aged 2 and older with sickle cell disease or thalassemia. This broadens the eligible patient population and strengthens Vertex's gene therapy franchise, though real-world uptake and reimbursement will determine the actual revenue impact.

    This regulatory win opens a new pediatric market for Casgevy, supporting long-term growth.

Q2 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

June 2026
▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

▲4

Vertex expands kidney, gene therapy, and rare disease reach

  • Kidney pipeline could add billions Vertex's kidney disease pipeline, including povetacicept and inaxaplin, is seen as a multi-billion-dollar growth driver. Positive late-stage data and a rolling FDA submission for povetacicept could diversify revenue beyond cystic fibrosis, lifting long-term sales expectations.

    This is a new growth opportunity that expands Vertex's revenue base and supports a higher valuation.

  • Casgevy approved for young children The FDA approved Casgevy for children as young as 2, expanding the market by about 5,500 U.S. patients and a $12.1 billion commercial opportunity. This regulatory win boosts Vertex's gene therapy revenue potential and strengthens its diversification story.

    A major regulatory expansion directly increases the addressable market and future sales for a key Vertex product.

  • Vertex to buy Crinetics for $10 billion Vertex agreed to acquire Crinetics Pharmaceuticals for about $10 billion, adding the acromegaly drug paltusotine and other assets. The deal is expected to immediately boost revenue and contribute to operating profit by 2029, with over $5 billion in peak annual revenue potential.

    This large acquisition expands Vertex's rare disease portfolio and provides near-term revenue growth, a key driver of the stock.

  • ALYFTREK gains Canadian reimbursement Vertex signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for ALYFTREK, making about 3,800 cystic fibrosis patients in Canada eligible. This expands access to Vertex's newest CF therapy, supporting incremental revenue growth in a core franchise.

    New reimbursement expands the market for a key cystic fibrosis product, directly supporting Vertex's revenue.

Amgen Inc (AMGN)

Q3 2026
▲3▼1

Amgen Q3: pipeline wins offset obesity and competition setbacks

  • Court blocks Colorado Enbrel price cap A court blocked Colorado's 70% price cap on Enbrel, protecting a key Amgen drug from a steep revenue cut. This legal win removes a major overhang and supports future sales.

    This is a new positive legal development that directly affects Amgen's revenue and stock sentiment.

  • Q2 earnings beat and raised guidance Amgen reported Q2 earnings per share of $6.29, beating expectations of about $5.60, and raised its full-year guidance. Growth products reached 70% of sales, showing the company's transition is working.

    This is a new positive financial update that exceeded expectations and boosted investor confidence.

  • Pipeline successes across multiple drugs Repatha cut mortality risk by 20%, Tezspire and dazodalibep showed positive results, and IMDELLTRA delivered landmark lung-cancer survival benefit with easier FDA monitoring. These advances strengthen Amgen's future revenue prospects.

    These are new clinical and regulatory wins that could drive future growth and lift earnings expectations.

  • Obesity hopes fade and competition rises Amgen discontinued its obesity drug AMG 513, and Novartis' pelacarsen failure cast doubt on Amgen's olpasiran, sinking shares about 10% and prompting a BMO downgrade. Meanwhile, Merck's cheaper oral PCSK9 and BMS's Sotyktu threaten Repatha and Otezla.

    This is a new negative development that hurt investor sentiment and the stock price, representing a key setback.

August 2026
▲3▼1

Amgen Q2 Beat and Pipeline Wins Lift Stock, But Risks Linger

  • Q2 earnings beat and raised guidance Amgen's Q2 2026 earnings beat expectations (EPS $6.29 vs. ~$5.60) and management raised full-year guidance, prompting analysts to lift price targets to $420–$460. This shows the company is performing better than expected and boosts investor confidence.

    This is the primary new event that drove the stock higher during the period.

  • Growth products now 70% of sales Repatha, Evenity, Uplizna, and Imdelltra grew 26% and now make up about 70% of Amgen's sales, reducing reliance on older drugs. This shift makes future revenue more stable and less exposed to patent cliffs.

    It highlights a fundamental improvement in Amgen's business mix that supports the stock.

  • Pipeline successes and cash from sale-leaseback Repatha cut death risk 20% in a major heart trial, Tezspire succeeded in eosinophilic esophagitis, and dazodalibep hit its Phase 3 goal in Sjögren's. A $151M Deerfield sale-leaseback added cash. These advances strengthen future growth prospects.

    These are new positive developments that could drive future revenue and cash flow.

  • Cyberattack, obesity setback, and drug-price risk A July cyberattack exposed patient data and triggered a class action investigation. Obesity hopes weakened after AMG 513 was discontinued, leaving MariTide trailing Lilly and Novo. A potential US drug-price agreement could pressure Medicaid revenue.

    These are new negative factors that could weigh on the stock and offset positive news.

Latest
▲4

Amgen Beats Q2, Wins Sjögren's Data, Sells Deerfield Campus

  • Q2 earnings beat lifts Amgen shares Amgen reported adjusted Q2 earnings of $6.29 per share, beating the $5.60 estimate, and shares rose 4.6%. Revenue also beat, showing the core business is growing faster than expected. This supports the stock because profits are the main driver of long-term value.

    The Q2 earnings beat is the period's biggest positive fundamental event and directly explains why AMGN moved up.

  • Positive Phase 3 data for dazodalibep in Sjögren's Amgen's dazodalibep met its main goal in a Phase 3 trial for systemic Sjögren's disease, a condition with no approved disease-modifying therapies. Success here adds a potential first-in-class drug to Amgen's pipeline, which can boost future sales and investor confidence.

    This is a new pipeline win that adds a future growth driver and supports the bull case for AMGN.

  • Deerfield campus sale-leaseback raises $151M cash Amgen sold its Deerfield office campus for $151 million and signed a long-term lease to stay in one building. This turns an illiquid property into cash without issuing shares or new debt, helping reduce the debt load from the Horizon acquisition. Shares rose 2.11% on the news.

    The sale-leaseback is a new capital move that improves Amgen's balance sheet and directly lifted the stock.

  • Analyst price targets raised on strong portfolio and Q2 beat Several banks including UBS, Argus, TD Cowen, Scotiabank and Oppenheimer raised Amgen price targets to $420–$460, citing a strong product portfolio, Q2 beats and higher guidance. Higher targets signal analysts see more upside, which can pull the stock up.

    The wave of target increases reflects improved analyst sentiment and is a key reason AMGN shares moved higher this period.

September 2026
▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

▲2▼2

Novartis Lp(a) Failure Sinks Amgen; IMDELLTRA Wins Offer Counterweight

  • Novartis Lp(a) failure casts doubt on Amgen's olpasiran Novartis' rival Lp(a)-lowering drug pelacarsen failed its Phase 3 heart trial, even though it lowered Lp(a). Amgen's similar drug olpasiran now faces the same doubt, and Amgen shares fell about 10% — their worst day since 2000 — as investors fear olpasiran may also fail to prevent heart attacks.

    This is the main new force driving AMGN down this period.

  • BMO downgrades Amgen on olpasiran risk BMO Capital downgraded Amgen to Market Perform from Outperform, keeping a $450 target but warning that olpasiran now carries more risk. A downgrade tells investors the analyst sees less upside, which can push the stock down and keep a lid on any recovery.

    Analyst downgrade is a direct new negative catalyst for the stock.

  • IMDELLTRA combo shows landmark survival benefit in lung cancer Amgen's IMDELLTRA combined with AstraZeneca's Imfinzi met its main goal in a Phase 3 lung-cancer study, significantly extending overall survival. This is the first such win for a bispecific T-cell engager in this setting, boosting confidence in a key new growth drug.

    A major positive pipeline win that offsets some of the Lp(a) pessimism.

  • FDA eases IMDELLTRA monitoring, making it easier to use The FDA approved a label update cutting required monitoring after the first two IMDELLTRA doses from 22–24 hours to 6–8 hours. Shorter monitoring makes the drug simpler to give, especially in community clinics, which could widen its use and support sales.

    Regulatory win that improves commercial practicality of a growth drug.

▲3▼1

Amgen Hits 52-Week High on Q2 Beat, Repatha and Tezspire Wins

  • Repatha Cuts Death Risk 20% in Major Heart Trial Amgen's Repatha reduced death risk by 20% in high-risk heart patients in the VESALIUS-CV trial, a major win for its biggest growth drug. This strengthens the case for wider use and future sales, supporting a higher stock price.

    This is a new, high-impact clinical win that directly boosts confidence in Amgen's key growth driver.

  • Tezspire Meets All Goals in Eosinophilic Esophagitis Trial Amgen and AstraZeneca's Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, a chronic throat condition with few good treatments. This opens a new market and adds to Tezspire's growth story, lifting investor optimism.

    New positive trial results expand a key product's potential, a fresh catalyst for the stock.

  • US Drug Price Agreement with Mid-Sized Biotechs Looms The Trump administration is expected to announce a drug price agreement with mid-sized biotech firms, and Amgen was among companies urged to cut US prices. If Amgen is included, lower Medicaid prices could pressure revenue and weigh on the stock.

    This is a new regulatory risk that could directly affect Amgen's pricing and profits.

  • Analyst Fair Value and Price Targets Raised After Q2 Beat Following Amgen's strong Q2 results, analysts raised their fair value estimate to about $372 and several price targets into the $450 range, citing broad franchise strength. Higher targets can pull the stock up as investors adjust expectations.

    This is a new analyst reaction that reflects upgraded expectations and can influence the stock price.

▲2▼2

Amgen Q2 Beat and Guidance Raise Outweigh Data Breach and Obesity Setback

  • Q2 earnings beat and raised 2026 guidance Amgen reported Q2 adjusted EPS of $6.29, well above the $5.62 consensus, and revenue of $10.05 billion, up 10% and ahead of forecasts. Management raised full-year revenue and EPS guidance, signaling confidence in the business. This directly boosts the stock as investors see stronger profits ahead.

    This is the main new positive event that drove the stock up over 5% this period.

  • Key growth drivers show strong momentum Six key products, including Repatha, Evenity, Uplizna, and Imdelltra, grew 26% year-over-year and now make up nearly 70% of product sales. This reduces reliance on older drugs like Enbrel and Otezla, which are facing competition. The shift supports future revenue growth and lifts investor confidence.

    It explains the underlying strength behind the earnings beat and why the stock rose.

  • Cybersecurity breach and class action investigation Amgen disclosed a July cyberattack where sensitive patient and proprietary data was stolen. A law firm has launched a class action investigation. This creates legal and reputational risk, which could weigh on the stock, though Amgen says operations are not materially affected.

    It is a new negative event that could pressure the stock and is important for a balanced view.

  • Obesity drug AMG 513 discontinued; MariTide faces tough competition Amgen ended development of early-stage obesity drug AMG 513, leaving MariTide as its only obesity candidate. MariTide's weight-loss data trails Eli Lilly's and Novo Nordisk's drugs, and switching patients may be hard. This raises doubts about Amgen's ability to compete in the lucrative obesity market.

    It is a new setback that could limit future growth and is a key counterweight to the positive earnings.

July 2026
▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

▼3▲1

Enbrel price cap blocked, but recalls and new rivals pressure Amgen

  • Court blocks Colorado's 70% Enbrel price cap A federal judge stopped Colorado from capping Enbrel's price by 70%. This removes a big worry that other states might follow, protecting Amgen's future sales and cash flow. The stock could rise as investors see less regulatory risk.

    This is a major new legal win that directly supports Amgen's revenue outlook.

  • Recalls of Corlanor and Sensipar raise quality concerns Amgen recalled some lots of heart drug Corlanor and kidney drug Sensipar due to foreign substances and manufacturing issues. This adds compliance risk and could lead to fines or lost sales, weighing on the stock as investors question production quality.

    New recalls create fresh regulatory and reputational risk that can hurt the stock.

  • New oral PCSK9 rival threatens Repatha Merck won FDA approval for Lipfendra, the first oral cholesterol drug in the same class as Amgen's injectable Repatha. It costs much less per month, so it could steal market share and slow Repatha's growth, pressuring Amgen's revenue.

    A new lower-priced competitor directly challenges a key Amgen growth drug.

  • Sotyktu launch may take share from Otezla Bristol Myers Squibb's new oral drug Sotyktu is gaining traction among arthritis doctors, and Amgen's Otezla is cited as likely to lose patients. This could reduce Otezla sales, a negative for Amgen's earnings outlook.

    New competitive data shows a direct threat to an existing Amgen product.

Q2 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

June 2026
▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.

▲2▼2

Amgen's growth drivers offset legal and regulatory setbacks

  • Growth drivers now 70% of sales Amgen's key growth drugs (Repatha, rare disease) grew 24% and now make up 70% of total sales, offsetting declines in older drugs. This shows the company's transition is working, which supports the stock price.

    This is the core positive force behind Amgen's business momentum.

  • MariTide and Repatha data advance Amgen's obesity drug MariTide is in phase 3 trials, and Repatha cut heart events by 29% in high-risk diabetes patients. These could become major new revenue sources, lifting future earnings expectations.

    Pipeline progress is a key driver of long-term growth and investor optimism.

  • Tavneos regulatory and data integrity crisis EU regulators recommend revoking Tavneos approval, and NEJM retracted the trial supporting it after FDA found data issues. The FDA may withdraw the drug in the US. This creates uncertainty and could hurt Amgen's reputation and sales.

    This is a major negative regulatory event that threatens a marketed drug and investor confidence.

  • Competition and patent risks Roche's divarasib beat Amgen's Lumakras in lung cancer, threatening Lumakras sales. Also, a jury found Amgen willfully infringed a patent, raising legal concerns. Both could pressure future revenue and increase costs.

    These are new competitive and legal threats that could weigh on Amgen's stock.